(S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market: Top 10 Companies Driving Global Chiral Synthesis

MARKET INSIGHTS

Global (S)-1-Cyclohexylethylamine (CAS 17430-98-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-1-Cyclohexylethylamine (CAS 17430-98-7) is a chiral amine compound characterized by a cyclohexyl group attached to an ethylamine backbone in its (S)-enantiomeric configuration. This specialty chemical serves as a critical building block and chiral auxiliary in asymmetric synthesis, pharmaceutical manufacturing, and agrochemical development. Its high enantiomeric purity makes it particularly valuable in the production of optically active intermediates used across drug discovery pipelines.

The market is gaining momentum primarily because of the expanding demand for enantiomerically pure compounds in pharmaceutical synthesis, where regulatory bodies increasingly require single-enantiomer drugs over racemic mixtures. Furthermore, growing investment in chiral chemistry research and the rising adoption of this compound as a resolving agent and ligand precursor are reinforcing market expansion. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other fine chemical manufacturers with established chiral amine portfolios.

(S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report

Top 10 Companies

BASF SE

Headquarters: Ludwigshafen, Germany

Key Offering: Pharmaceutical‑grade chiral amines, advanced process chemistry solutions.

BASF’s integrated research and manufacturing capabilities allow it to supply high‑purity (S)-1‑Cyclohexylethylamine at scale, supporting API development for CNS and oncology candidates.

Sustainability Initiatives:

• Investment in renewable feedstocks for chiral synthesis.
• Carbon‑neutral production targets by 2030.
• Transparent life‑cycle assessment reporting.

Evonik Industries AG

Headquarters: Essen, Germany

Key Offering: cGMP‑compliant chiral intermediates and catalyst development.

Evonik’s focus on process efficiency and quality control positions it as a trusted supplier for pharmaceutical and agrochemical customers seeking consistent enantiomeric excess.

Sustainability Initiatives:

• Waste‑minimisation programmes in fine‑chemical units.
• Use of green solvents in asymmetric hydrogenation.
• Participation in the EU Green Deal industrial roadmap.

Jiangsu Hengrui Medicine Co., Ltd.

Headquarters: Nanjing, China

Key Offering: Large‑scale synthesis of chiral amines for API manufacturing.

Hengrui’s robust production infrastructure and strong regulatory alignment enable it to meet the growing demand from domestic and international pharmaceutical firms.

Sustainability Initiatives:

• Energy‑efficient reactor design.
• Water‑recycling systems in chemical production.
• Strategic partnerships with global pharma companies.

Shandong Xinhua Pharmaceutical Co., Ltd.

Headquarters: Jinan, China

Key Offering: High‑purity chiral amines and resolving agents.

Shandong Xinhua’s focus on quality assurance and rapid turnaround times supports the fast‑paced API development cycles of multinational pharma clients.

Sustainability Initiatives:

• Implementation of ISO 14001 environmental management.
• Reduction of hazardous solvent usage.
• Continuous improvement through Six Sigma.

TCI Chemicals (Tokyo Chemical Industry Co., Ltd.)

Headquarters: Tokyo, Japan

Key Offering: Catalog‑grade chiral amines for research and development.

TCI’s global distribution network and extensive technical support make it a preferred choice for academic and industrial laboratories seeking reliable reagents.

Sustainability Initiatives:

• Eco‑friendly packaging solutions.
• Promotion of green chemistry workshops.
• Carbon footprint monitoring across facilities.

Alfa Aesar

Headquarters: St. Louis, United States

Key Offering: Specialty chemical catalog and custom synthesis services.

Alfa Aesar’s flexible ordering platform and rapid sample delivery cater to the needs of small‑to‑mid‑size R&D teams and contract manufacturers.

Sustainability Initiatives:

• Recycling of chemical waste streams.
• Use of renewable electricity in production sites.
• Support for green chemistry education initiatives.

Alfa Chemistry

Headquarters: Cleveland, United States

Key Offering: Custom synthesis of chiral intermediates.

Alfa Chemistry’s expertise in small‑scale, high‑purity synthesis supports niche applications in drug discovery and agrochemical research.

Sustainability Initiatives:

• Optimisation of reaction conditions to minimise waste.
• Adoption of biocatalytic routes for chiral amines.
• Engagement with industry consortia on sustainability standards.

Hangzhou Dayangchem Co., Ltd.

Headquarters: Hangzhou, China

Key Offering: Cost‑effective chiral amine production with stringent quality controls.

Dayangchem’s focus on scalable processes and regulatory compliance makes it a competitive supplier in the Asian market.

Sustainability Initiatives:

• Energy‑efficient manufacturing processes.
• Use of biodegradable solvents.
• ISO 9001 quality management integration.

Nanjing Chemlin Chemical Industry Co., Ltd.

Headquarters: Nanjing, China

Key Offering: Advanced chiral amine synthesis and catalyst development.

Chemlin’s research‑driven approach aligns with the needs of pharmaceutical companies seeking innovative building blocks.

Sustainability Initiatives:

• Implementation of green chemistry principles in core processes.
• Investment in renewable energy sources.
• Collaboration with academic institutions on sustainable synthesis.

Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany

Key Offering: Comprehensive catalog of chiral reagents and analytical services.

Sigma‑Aldrich’s extensive analytical capabilities support end‑users in verifying enantiomeric purity and compliance with regulatory standards.

Sustainability Initiatives:

• Reduction of hazardous waste through process optimisation.
• Use of bio‑based feedstocks where possible.
• Transparent sustainability reporting across the supply chain.

Alfa Aesar

Headquarters: St. Louis, United States

Key Offering: Specialty chemical catalog and custom synthesis services.

Alfa Aesar’s flexible production and rapid turnaround meet the demands of researchers and contract manufacturers alike.

Sustainability Initiatives:

• Recycling of chemical waste streams.
• Use of renewable electricity in production sites.
• Support for green chemistry education initiatives.

Download FREE Sample Report: (S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report

Get Full Report: (S)-1-Cyclohexylethylamine (CAS 17430-98-7) Market – View in Detailed Research Report

Market Outlook

Over the next decade, the demand for enantiomerically pure intermediates will continue to rise as pharmaceutical development moves toward single‑enantiomer therapies. The integration of biocatalytic routes and flow chemistry is expected to lower production costs and improve scalability, enabling smaller players to compete in niche markets.

Future Trends

Key trends shaping the market include the adoption of enzyme‑based synthesis for chiral amines, the expansion of agrochemical applications requiring stereoselectivity, and the push for sustainability metrics across the supply chain. Companies that embed green chemistry principles into their core processes will likely capture a larger share of the market, especially among regulators and customers prioritising environmental performance.